Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Restore Myocardial Function With CorMatrix® ECM® Particulate (P-ECM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02139189
Recruitment Status : Completed
First Posted : May 15, 2014
Last Update Posted : July 19, 2017
Sponsor:
Information provided by (Responsible Party):
CorMatrix Cardiovascular, Inc.

Brief Summary:
The purpose of this CorMatrix P-ECM safety and feasibility study is to evaluate the safety and functional effect of the CorMatrix P-ECM.

Condition or disease Intervention/treatment Phase
Heart Failure Device: P-ECM Implant Not Applicable

Detailed Description:
Evaluate the safety of the CorMatrix ECM Particulate (P-ECM) delivered trans-epicardially to subjects with left ventricular ejection fraction (LVEF) 25 to 40% during coronary artery bypass grafting (CABG)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RESTORE Myocardial Function With CorMatrix® ECM® Particulate (P-ECM) Implantation in Subjects With LVEF 25 to 40% Study
Study Start Date : June 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Arm Intervention/treatment
Experimental: P-ECM Implant
P-ECM Implant into damaged ischemic and/or infarcted myocardium
Device: P-ECM Implant
P-ECM Implant into damaged ischemic and/or infarcted myocardium




Primary Outcome Measures :
  1. Subject-level incidence of serious adverse device effects (SADEs) or serious implantation procedure-related adverse events that occur within 6 months of implantation of the P-ECM [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 18 to 75 years of age
  • Ischemic cardiomyopathy with LVEF 25 to 40% as determined by resting cardiac echocardiography
  • Subjects with severe chronic ischemic cardiomyopathy manifested by Canadian Cardiovascular Society (CCS) class II or greater angina, and/or New York Heart Association (NYHA) class II or greater dyspnea
  • Patients who have undergone diagnostic coronary angiography demonstrating > 70% diameter narrowing of at least two major coronary arteries or branches OR > 50% diameter narrowing of the left main coronary artery
  • Significant left ventricular systolic dysfunction evaluated by echocardiography or LV angiography (LVEF 25 to 40%) due to a prior myocardial infarction. This area of left ventricular dysfunction should be akinetic or severely hypokinetic, not aneurysmal, when assessed by echocardiography or LV angiogram

Exclusion Criteria:

  • Need for urgent or emergent revascularization
  • Patients with confirmed myocardial infarction within 14 days, and/or rising cardiac biomarker proteins (i.e., CK-MB or troponin), and/or worsening ECG changes
  • Patient supported by balloon pump pre-op
  • Moderate or severe (> 1+) aortic insufficiency as determined by echocardiogram
  • History of severe ventricular tachyarrhythmias requiring treatment
  • Hypertrophic obstructive cardiomyopathy (HOCM), restrictive cardiomyopathy, or congenital heart disease
  • Prior cardiac operations
  • Anticipated for concomitant surgical procedure at the time of CABG (e.g., valve repair or replacement, aneurysm resection, carotid endarterectomy, etc.)
  • Active infection, with a temperature greater than 37.5°C and an unexplained white blood cell count in excess of 15,000/mm3 within 48 hours prior to surgery
  • Hemoglobin less than 10g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3
  • Primary coagulopathy or platelet disorder, including thrombocytopenia with absolute platelet count < 80k or active state of disseminated intravascular coagulation
  • Hemodynamically unstable patients, as defined by heart rate <40/min or >100/min, and/or systolic blood pressure <90 mmHg or >200 mmHg, and/or ongoing need for intravenous inotropic or vasopressor medications
  • Severe pulmonary hypertension as defined by PVR > 8 Wood units, that is unresponsive to vasodilator therapy within 14 days of enrollment
  • History of stroke or a history of cerebral vascular disease with significant (> 80%) extra cranial stenosis, without evidence of collateral flow. (Patients with cerebral vascular disease history must have acceptable stenosis documented by a carotid doppler study)
  • Severe chronic renal insufficiency (serum creatinine >2.5mg/dl, estimated glomular filtration rate (eGFR) <35 mL/min/1.73m2 or need for dialysis)
  • Evidence of intrinsic hepatic disease as defined as liver enzyme values (AST or ALT or total bilirubin) that are > 5 times the upper limit of normal within 30 days of enrollment (diagnosis of cirrhosis, chronic hepatitis), except in association with acute decompensation as determined by the Investigator
  • Significant peripheral vascular disease defined by claudication, rest pain or leg ulceration
  • Positive laboratory test results or a history of syphilis, Hepatitis B Virus, Hepatitis C Virus, Human T-Lymphotropic Virus Type 1 and 2, and Human Immunodeficiency Virus
  • Active or known non-dermatological malignancy undergoing treatment including chemotherapy and radiotherapy or any other condition that would place the patient at increased risk for complications during the first 6 months after the procedure in the judgment of the attending cardiologist or cardiac surgeon
  • Immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)
  • Previous solid organ transplantation or anticipated need for solid organ transplant other than heart (with the exception of corneal transplant)
  • Hematological disorders (e.g., aplastic anemia) or bone marrow disorders
  • Myelodysplastic syndrome
  • Any condition associated with a life expectancy of less than 6 months
  • Contraindications to magnetic resonance imaging (MRI) including presence of an implantable cardiac defibrillator (ICD) or permanent pacemaker (PPM), or cases in which it is anticipated that an ICD or PPM will be implanted prior to the 6 month follow-up or claustrophobia (thus precluding performance of follow-up MRI scans)
  • Contraindication to the administration of heparin, warfarin or anti-platelet agents
  • Known allergic reaction or sensitivity to porcine material
  • Significant cognitive impairment or psychiatric disease (including drug or alcohol abuse) that is likely to impair compliance with the study protocol
  • Current participation or participation within the last 3 months in the study of an investigational drug, device, or biologic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02139189


Locations
Layout table for location information
Poland
Central Clinical Hospital of the Ministry of the Interior in Warsaw
Warsaw, Poland, 02-507 Warsaw
Sponsors and Collaborators
CorMatrix Cardiovascular, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Piotr Suwalski, Professor Central Clinical Hospital of the Ministry of Interior in Warsaw
Layout table for additonal information
Responsible Party: CorMatrix Cardiovascular, Inc.
ClinicalTrials.gov Identifier: NCT02139189    
Other Study ID Numbers: 13-PR-1083
First Posted: May 15, 2014    Key Record Dates
Last Update Posted: July 19, 2017
Last Verified: July 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases